title: Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition.
abstract: Poor behavioral inhibition is a common feature of neurological and psychiatric disorders. Successful inhibition of a prepotent response in 'NoGo' paradigms requires the integrity of both the inferior frontal gyrus (IFG) and the serotonergic system. We investigated individual differences in serotonergic regulation of response inhibition. In 24 healthy adults, we used (18)F-altanserin positron emission tomography to assess cerebral 5-HT2A receptors, which have been related to impulsivity. We then investigated the impact of two acute manipulations of brain serotonin levels on behavioral and neural correlates of inhibition using intravenous citalopram and acute tryptophan depletion during functional magnetic resonance imaging. We adapted the NoGo paradigm to isolate effects on inhibition per se as opposed to other aspects of the NoGo paradigm. Successful NoGo inhibition was associated with greater activation of the right IFG compared to control trials with alternative responses, indicating that the IFG is activated with inhibition in NoGo trials rather than other aspects of invoked cognitive control. Activation of the left IFG during NoGo trials was greater with citalopram than acute tryptophan depletion. Moreover, with the NoGo-type of response inhibition, the right IFG displayed an interaction between the type of serotonergic challenge and neocortical 5-HT2A receptor binding. Specifically, acute tryptophan depletion (ATD) produced a relatively larger NoGo response in the right IFG in subjects with low 5-HT2A BPP but reduced the NoGo response in those with high 5-HT2A BPP. These links between serotonergic function and response inhibition in healthy subjects may help to interpret serotonergic abnormalities underlying impulsivity in neuropsychiatric disorders.
authors.affiliation: Danish Research Centre for MR, Copenhagen University Hospital, Hvidovre, Denmark.
authors.forename: Julian
authors.initials: J
authors.lastname: Macoveanu
authors.forename: Bettina
authors.initials: B
authors.lastname: Hornboll
authors.forename: Rebecca
authors.initials: R
authors.lastname: Elliott
authors.forename: David
authors.initials: D
authors.lastname: Erritzoe
authors.forename: Olaf B
authors.initials: OB
authors.lastname: Paulson
authors.forename: Hartwig
authors.initials: H
authors.lastname: Siebner
authors.forename: Gitte M
authors.initials: GM
authors.lastname: Knudsen
authors.forename: James B
authors.initials: JB
authors.lastname: Rowe
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D015283:Citalopram / Q000494:pharmacology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007266:Inhibition, Psychological; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D010775:Photic Stimulation / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology*; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism*; D014364:Tryptophan / Q000172:deficiency* / Q000378:metabolism; D055815:Young Adult
chemical_list: D044402:Receptor, Serotonin, 5-HT2A; D015283:Citalopram; D014364:Tryptophan